Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Sonia Contreras (Valencia, Spain), Sonia Contreras, Javier Milara, Adela Serrano, Esteban Morcillo, Julio Cortijo. Roflumilast N-oxide combined with PI3Kδ inhibitor improves the phenotype of early-onset COPD. Eur Respir J 2016; 48: Suppl. 60, 4087

Member's Comments

No comment yet.

Related content which might interest you: Experience of application the selective phosphodiesterase-4 inhibitor roflumilast in the patient with COPD and the metabolic syndrome Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 Erdosteine improves airflow in patients with severe exacerbation of COPD (AECOPD) Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 Long term treatment with n-acetylcysteine reduces exacerbations in moderate chronic obstructive pulmonary disease Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 Roflumilast added to triple therapy in severe COPD patients with frequent exacerbations: Efficacy and tolerability Source: International Congress 2014 – Markers Year: 2014 PF-03715455: An inhaled p38 inhibitor for the treatment of chronic obstructive pulmonary disease Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013 Pharmacological activities of roflumilast N-oxide, dexamethasone and formoterol in human neutrophils from healthy non-smokers and COPD patients Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 Measurement properties of exacerbations of chronic pulmonary disease tool (EXACT) in a clinical trial of patients with moderate to severe COPD Source: Annual Congress 2013 –Monitoring symptoms and quality of life Year: 2013 Reduction in systemic inflammation by the PDE4 inhibitor roflumilast in patients with COPD Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 The role of IFN-γ in severe COPD patients with anamnestic viral-induced exacerbations before and after roflumilast treatment Source: International Congress 2016 – Translational studies in lung disease Year: 2016 Clinical evaluation of a new inhibitor of neutrophilic inflammation, tetomilast (OPC-6535), in chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2006; 28: Suppl. 50, 527s Year: 2006 Can roflumilast improve clinical outcomes in moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis Source: International Congress 2016 – COPD diagnosis and management Year: 2016 PPAR-alpha agonist (fenofibrate) therapy in exacerbation control of chronic obstructive pulmonary disease of severe stage Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Efficacy of roflumilast in the frequent exacerbation COPD phenotype Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011 Once-daily glycopyrronium improves lung function and reduces exacerbations in severe-to-very severe COPD patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 Roflumilast with long-acting ?2-agonists for COPD: influence of exacerbation history Source: Eur Respir J 2011; 38: 553-560 Year: 2011 Factors associated with exacerbation in a general practitioners’-based Swiss chronic obstructive pulmonary disease (COPD) cohort Source: Annual Congress 2013 –The best posters in chronic care Year: 2013 Safety of the PDE4 inhibitor roflumilast in COPD patients with chronic bronchitis Source: Annual Congress 2009 - Treatment of COPD Year: 2009 Efficacy of the PDE4 inhibitor roflumilast in COPD patients with chronic bronchitis Source: Annual Congress 2009 - Treatment of COPD Year: 2009 Chronic kidney disease as effect modifier in the association between the use of tiotropium respimat and mortality Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD Year: 2013 Mukoregulatory drugs in treating COPD Source: International Congress 2014 – Predictors Year: 2014